PREDIAPT: Development of a Predictive System based on Aptamers in Response to Treatment with Platinum Derivatives in Lung Cancer.
The PREDIAPT project develops two prognostic applications for response to treatment with platinum derivatives in lung cancer using MAFG as a diagnostic biomarker through (i) a system based on the ELONA technique, using aptamers as a recognition molecule, which will detect MAFG levels in blood and will allow monitoring of the disease in liquid biopsy and (ii) a prognostic system based on histochemistry using aptamers against MAFG in tumor tissue samples. The objective is to put the two products into clinical practice to improve the management of patients with non-small cell lung cancer (NCLC).
The consortium is made up of the two research centres that pioneered the idea, IRYCIS and IdiPAZ, together with two biotech companies with extensive experience in the development of aptamers and diagnostic techniques, AptusBiotech and ATRYS Health. The leader of the consortium will be APTUS, a leading company in the development of new applications based on aptamers, which will design and create the diagnostic systems with the support of the IRYCIS Aptamer Group for validation in the laboratory. The systems will later be analytically and clinically validated by the company ATRYS Health, an expert in the study and validation of biomarkers through different methodological approaches, together with IRYCIS and IdiPAZ, which will also be in charge of obtaining clinical samples from patients. The introduction in the
market of the products developed in the PREDIAPT project would imply an improvement in the decision making of the treatment of patients with lung cancer, as well as a great economic impact in the public health system.